Document Detail


Treatment of childhood kaposiform hemangioendothelioma with sirolimus.
MedLine Citation:
PMID:  20730884     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which has been used extensively in children following solid organ transplantation, has been demonstrated to have anti-angiogenic activity in pre-clinical models. Limited experience suggests that it may have application to the treatment of vascular lesions. We describe our experience with a 1-year-old female with a kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon who had rapid and dramatic response to sirolimus (0.1 mg/kg/day). This case provides further rationale for clinical trials of sirolimus in the treatment of vascular lesions.
Authors:
Julie Blatt; Joseph Stavas; Billie Moats-Staats; John Woosley; Dean S Morrell
Related Documents :
18822934 - Diffuse cavernous hemangioma of the spleen with kasabach-merritt syndrome misdiagnosed ...
19022024 - Hemangioma of the sternum.
11448074 - The role of tc-99m rbc scintigraphy in the differential diagnosis of orbital cavernous ...
24813844 - Confluent and reticulated papillomatosis (gougerot-carteaud syndrome) in two brothers.
1416394 - Idiopathic pulmonary fibrosis. quantitative assessment of lung pathology. comparison of...
20495634 - Clinical factors predictive of malignant and premalignant cystic neoplasms of the pancr...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Pediatric blood & cancer     Volume:  55     ISSN:  1545-5017     ISO Abbreviation:  Pediatr Blood Cancer     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-10-28     Completed Date:  2010-11-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101186624     Medline TA:  Pediatr Blood Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1396-8     Citation Subset:  IM    
Affiliation:
Division of Pediatric Hematology Oncology, Vascular Lesions Clinic, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. jblat@med.unc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenesis Inhibitors / therapeutic use*
Antibiotics, Antineoplastic / therapeutic use*
Female
Hemangioendothelioma / blood,  drug therapy*,  pathology
Humans
Infant
Platelet Count
Sirolimus / therapeutic use*
Skin Neoplasms / blood,  drug therapy*,  pathology
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibiotics, Antineoplastic; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sexual function in adolescent and young adult survivors of lower extremity bone tumors.
Next Document:  Breast metastases in children and adolescents with rhabdomyosarcoma: Experience of the Italian Soft ...